Member Info for Computer909

@Silles: We discussed this in January, when you try to schedule the test, you aren't given the option of the Visitect Antibody test, when i queried the company they said they weren't available but offered the Dutch Biozek antibody test instead

So when can we realistically expect (keeping in mind this is ODX and they work to a whole different speed than the rest of the universe) any news on EU submission being complete or even approval, anyone have a clue ?

We are just 5 days away from being 8 months, yes 8 months since CK said

“We welcome the news that Mologic has received CE Mark for its Rapid Antigen Test, and are excited about completing the technology transfer and CE Marking in the New Year."

4 months since the commercial launch

Still not a single sale or even distribution agreement worthy of notification, how the hell is that “Well placed”?

@Convex101: We will never really know what actually went on during that friday evenings intoxicated discussions between ODX and Walbrook,

The Company were given the opportunity to let us know in the investor QA:

Q121: The “Tesla” tweet had a massive negative impact on the Omega share price and cost its investors millions of pounds, can you confirm who in the company was responsible for that tweet and whether they were suitable reprimanded or indeed their engagement terminated."

But side stepped the question.

With regards the "Delivery" tweets in February preceeding the issues with Mologic validation, I probably agree with you, the question being how much did the PMDR know at that time, and did that explain them offloading at the top of the market, only days after announcing a "transformational DHSC contract" and does this also explain the downbeat nature of the contract announcement RNS ?

@Convex101: With regards the Tesla tweet this was the response from Walbrook when queried where the tweet came from:

"The tweet was provided as the Company agreed that it was evident from posts on twitter and emails received from investors that there was a worrying misconception that the additional Government disclosure made on Friday had somehow confirmed a contract award of £374m (beyond what had already been previous disclosed in March) or that Omega had in some way had purchase orders for this value confirmed

We discussed this with the Company on Friday evening and believe the approach reflects the Omega’s desire to be honest and clear with shareholders, to ensure that expectations on future performance are correct, and that investors are not mislead or deceived by false information or an incorrect interpretation of the Government disclosure."

@Convex101: I am referring to the time period around 16th & 17th February when ODX tweeted the now infamous "This April, We'll deliver 2m rapid LFT's a week" over the top of increased government rollout and "delivery" of LFT, whilst just a day later we get notified of PDMR holdings being sold.

These are the only communications in the pandemic period ODX have ever referred to anything other than "Capacity', and actually stated delivery figures, the question is why ?

*Section 14, page 77

@TWatcher: "13K a day is only 91K a week,"

Section 14, page 71 https://atamis-1928.cloudforce.com/sfc/p/#0O000000rwim/a/4J000000QFuh/xNrDI1AdChq3YAdDpRA23vHB0amNyHVtJraCxfQxoRc

The Volumes talked about in the Thriva contract are way off those figures

@Convex101: "The only comms I take issue with is the Tesla tweet which came from Walbrook."

So you are comfortable with the two "This April we will deliver 2M tests per week" tweets in April, 2 days before PDMR options get sold ?

And Walbrook actually stated the Tesla tweet came from the company itself

Looks like the Thriva contracts department have learnt from the Abingdon debacle ,and is much more commercially astute when dealing with the DHSC charlatans

“Where DHSC disputes an invoice issued by the Supplier, the Parties shall liaise with each other and seek to agree a resolution to such dispute within seven (7) days of the dispute being raised. If the Parties are unable to agree a resolution within a further fourteen (14) days the dispute being raised then such dispute shall be referred to dispute resolution in accordance with theDispute Resolution Procedure. For the avoidance of doubt, DHSC shall not be in breach of any of its payment obligations under this Agreement in relation to any disputed invoice sums unless the process referred to in this clause 16.2 has been followed and it has been determined that the disputed invoice amount is properly due to the Supplier and DHSC has then failed to pay such sum within seven (7) days of such determination.

The Supplier reserves the right to cancel any disputed invoice and to raise a new invoice to reflect the amount on the relevant invoice that is not in dispute. DHSC shall pay any undisputed amounts in accordance with the provisions of this Agreement. Any disputed amounts will beresolved in accordance with clause 16.2 above. “

@CalderKate: "Cannot just fob people off, questions will need to be answered, an investigations will need to be done and anyone who has done anything wrong will be held accountable surely not"

If you are talking about government officials the worst that will happen to them will be moved sideways or fired from office, if they are MP's the will disappear to the back benches an pop up now and again whilst still claiming their £60K salary and expenses. Look at the David Cameron scandal, a lot of noise but no real action and he's still sat with $10M in the bank whilst the Greensill investors have lost millions.

Questions will inevitably be asked in the public enquiry but that will not deliver for 3-5 years by then Boris and his cronies will have moved on and taken up their lucrative consultant roles in wealthy companies that have done extremely well out of the pandemic.

@Jholder: More than happy to hear from you the details of what underpins the current price, Just because i know what i am invested in and am comfortable with it.

Information is there to be digested and decided upon, acted on or ignored, I have said before private antigen sales is the play for ODX (i was hoping for that to push us over 100p but would be happy with 80p now) as this looks like a major screw up from senior management on that front at the moment.

@Calpos: I think i answered this yesterday

"
@wadogara: i think i have said before that the non covid business was likley to be worth 30-40p, but i think a lot has changed in the last couple of months, on the CD4 front our biggest supporter CHAI, could very quickly become our biggest competitors with the Mologic/ GAD buyout, and the current market has all but disappeared with the impact of covid in those countries, or at least the focus is no longer there for the foreseeable , food intolerance is another unknown but doesnt look to have gained much traction in china even though they have been pretty much back to normal for a year now.

So what underpins the 30-40p non-covid value, well it definitely isnt backed by results, with £9m revenue and £2.2m loss, and it isn’t tangible assets, they are just over £20m, so the only thing is market sentiment, and that looks to be evaporating rapidly,

The reality is that without delivering on the covid commercial opportunities we could very easily be back to pre-covid levels of the 20s, and when Covid opportunites i dont mean a bit of cassette and pouching work,

We need regulator approvals and sales PDQ "

@Siles: "just CD4 side of business is worth more and the good thing is that the 1m/2m capacity is flexible"

https://www.brrmedia.co.uk/broadcasts/5f84724bc4d0076f2b93e3c5/omega-diagnostics-group-product-sector-overview-cd4/
@3.55

CD4 is no where near going to support the current mcap, as John Bannister says Omega should be positioned to supply 4-6M tests per year in the next 3-5 years, at a supply cost of $4 per test

4-6M tests a year out of a 1M a week capacity !

The development of additional complimentary tests for CD4 (which we were led to believe a proportion of the placing funds were for, haven't even started development, and would be 2-3 years away at least

Anyone saying ODX isn't a Covid stock at this price is mistaken i am afraid.

@RegulatorUK: "On Feb 17th, Omega tweeted: "This April, we'll deliver 2m rapid LFTs per week." Now put it into context...

Lets do exactly that, Omega stated "This April, we'll deliver 2M rapid LFTs per week", over the top of a news article stating "NHS test and Trace is readying for nationwide surge testing under which 400,000 rapid tests will be sent by post to homes and workplaces every day"

"Government preparing for mass testing 'blitz' as part of plan to lift lockdown , government aiming to deliver up to 75M tests a week by April"

It was clear that ODX were using the same wording "Deliver" to give the impression they would be part of the stated rollout.

Thats the context of the second tweet (17th February), in the same week that the DHSC contract was announced and everything looked rosy in the ODX garden, little did we know at the time, those roses were covered in horse s h i t

@Sledgey121: Which part ?

Innova May Payment : £330M
Innova April Payment £181M

ODX MCap £79M
ABDX MCap 31M
AVACT MCap 293M

?

ironic isn't it the the DHSC are refusing to pay ADBX whats owed to them for goods supplied and used so they are making uk staff redundant, and yet in May they paid Innova enough (£330M) to buy out ABDX and ODX and still have over £200M left over, if you take the last two innova payments, they could have AVACTA as well.

Well done Borris truly outstanding support.

@wadogara: i think i have said before that the non covid business was likley to be worth 30-40p, but i think a lot has changed in the last couple of months, on the CD4 front our biggest supporter CHAI, could very quickly become our biggest competitors with the Mologic/ GAD buyout, and the current market has all but disappeared with the impact of covid in those countries, or at least the focus is no longer there for the foreseeable , food intolerance is another unknown but doesnt look to have gained much traction in china even though they have been pretty much back to normal for a year now.

So what underpins the 30-40p non-covid value, well it definitely isnt backed by results, with £9m revenue and £2.2m loss, and it isn’t tangible assets, they are just over £20m, so the only thing is market sentiment, and that looks to be evaporating rapidly,

The reality is that without delivering on the covid commercial opportunities we could very easily be back to pre-covid levels of the 20s, and when Covid opportunites i dont mean a bit of cassette and pouching work,

We need regulator approvals and sales PDQ

@wadogara: You say "Core business will support current SP", what exactly to do base that on ?

Airports call for PCR tests to be replaced with cheaper LFT

https://www.proactiveinvestors.co.uk/companies/news/957427/heathrow-airport-berates-government-over-covid-19-test-costs-as-passenger-numbers-return-to-march-2020-levels-957427.html